Tag:
neuroscience
Latest Headlines
Latest Headlines
Big Pharma's high-risk pursuit of CNS gold faces major market doubts
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
Pharma giants offer up drug candidates for $20M NIH collaboration
The idea is simple: The drug companies will offer up their data and investigators will have a chance to explore new uses, with a set of deal templates in place to help speed the process on 20 programs.
Researchers coax immature brain stem cells from connective tissue
Stem cell news alert: Scientists at the University of Bonn in Germany were able to coax immature brain stem cells from mouse connective tissue.
Novartis joins exodus from traditional R&D neuroscience drug work
Novartis ( $NVS ) is joining the global exodus from the field of traditional drug research for brain disorders. Nature reports that the pharma giant has set in motion plans to shut down its
J&J seeds an ambitious open R&D program for neuroscience
J&J neuroscience R&D chief Dr. Husseini Manji
Just how far can you go with an open R&D approach to drug development? Johnson & Johnson ( $JNJ ) is stepping up with $3
J&J neuroscience chief advocates "open" R&D program
One of the most hotly debated issues in R&D circles revolves around the big research silos Big Pharma and quite a few biotechs have built around their IP . Desiring to keep a solid grasp on their
Neuroscience groups alarmed as pharma bolts brain drug R&D
Facing an unusually high risk of failure at the same time investors are demanding that Big Pharma show them the new products, a slate of European companies has dropped out or scaled back work in
